Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02614326
Other study ID # MemFlex to prevent relapse
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 2016
Est. completion date December 2020

Study information

Verified date May 2021
Source Medical Research Council Cognition and Brain Sciences Unit
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A wealth of research has demonstrated that they way in which the investigators recall our personal, autobiographical memories is influential in the course of depression. Biases in the recall of autobiographical memory occur in the midst of a depressive episode, and are shown to prolong symptoms, however these biases also remain when depression remits, and may predispose the individual towards relapse. A novel cognitive intervention, MemFlex, aims to train individuals to be flexible in their retrieval of autobiographical memories, and thereby reduce depressive relapse. Changes in memory bias may also have an effect on intermediate processes that increase risk of depression, such as rumination, impaired problem solving, and cognitive avoidance. This feasibility trial compares the effects of MemFlex and Psychoeducation in their ability to reduce memory bias and intermediate cognitive risk factors, and thereby depressive relapse, in individuals remitted from Major Depressive Disorder. Clinical outcome and process measures will be assessed immediately following completion of the intervention, at 6 months post-intervention, and at 12 months post-intervention. If encouraging, the results of this pilot trial may provide a foundation for a later phase trial.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date December 2020
Est. primary completion date August 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Meets criteria for Major Depressive Disorder but is currently in remission, indexed on the Structured Clinical Interview for the DSM (SCID; First et al., 1996) - 18 years of age or older Exclusion Criteria: - Meets criteria for a current Major Depressive Episode, indexed on the SCID - Meets criteria for another mood disorder (e.g., Bipolar disorder), indexed on the SCID - Current alcohol or substance dependence, or currently experiencing psychotic symptoms, indexed on the SCID - Experience of intellectual disability, traumatic brain injury, or other neurological condition which may impact memory recall, assessed via self-report

Study Design


Intervention

Behavioral:
Autobiographical Memory Flexibility (MemFlex) training
As in experimental arm description
Psychoeducation
As in experimental arm description

Locations

Country Name City State
United Kingdom Cambridge and Peterborough NHS Foundation Trust Cambridge
United Kingdom MRC Cognition and Brain Sciences Unit Cambridge

Sponsors (1)

Lead Sponsor Collaborator
Medical Research Council Cognition and Brain Sciences Unit

Country where clinical trial is conducted

United Kingdom, 

References & Publications (9)

Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the hopelessness scale. J Consult Clin Psychol. 1974 Dec;42(6):861-5. — View Citation

Beck, A. T., & Steer, R. A. (1993). Beck Anxiety Inventory Manual. San Antonio, TX: Psychological Corporation.

Beck, A., Steer, R., & Brown, G. (1996). Manual for the Beck Depression Inventory II. San Antonio, TX: Psychological Corporation.

Dritschel B, Beltsos S, McClintock SM. An "alternating instructions" version of the Autobiographical Memory Test for assessing autobiographical memory specificity in non-clinical populations. Memory. 2014;22(8):881-9. doi: 10.1080/09658211.2013.839710. Epub 2013 Nov 12. Erratum in: Memory. 2014;22(5):i. Beltosis, Stamatis[corrected to Beltsos, Stamatis]. — View Citation

First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York: Biometrics Research, New York State Psychiatric Institute.

Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, Andreasen NC. The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987 Jun;44(6):540-8. — View Citation

Marx EM, Williams JM, Claridge GC. Depression and social problem solving. J Abnorm Psychol. 1992 Feb;101(1):78-86. — View Citation

Sexton KA, Dugas MJ. The Cognitive Avoidance Questionnaire: validation of the English translation. J Anxiety Disord. 2008;22(3):355-70. Epub 2007 Apr 25. — View Citation

Treynor, W., Gonzalez, R., & Nolen-Hoeksema, S. (2003). Rumination reconsidered: A psychometric analysis. Cognitive Therapy and Research, 27, 247-259. doi: 10.1023/A:1023910315561

Outcome

Type Measure Description Time frame Safety issue
Other Rumination Total and sub-scale scores on the Rumination Response Scale (Treynor, Gonzalez, Nolen-Hoeksema, 2003) Measured within one week of completing the intervention, six months post-intervention and 12 months post-intervention
Other Problem solving The total number of means and total effectiveness scores on the abbreviated version of the Means-Ends Problem Solving task (Marx, Williams, & Claridge, 1992) Measured within one week of completing the intervention, and six months post-intervention
Other Cognitive avoidance Total score on the Cognitive Avoidance Questionnaire (Sexton & Dugas, 2008) Measured within one week of completing the intervention, six months post-intervention and 12 months post-intervention
Other Anxiety symptoms Total score on the Beck Anxiety Inventory (Beck & Steer, 1993) Measured within one week of completing the intervention, six months post-intervention and 12 months post-intervention
Other Hopelessness Total score on the Beck Hopelessness Scale (Beck, Weissman, Lester, & Trexler, 1974) Measured within one week of completing the intervention, six months post-intervention and 12 months post-intervention
Primary Time to depressive relapse Length of time from post-intervention assessment to occurrence of any major depressive episode within the 12 month follow-up period 12 months post-intervention
Primary Number of depression free days at 12 month follow-up Number of depression free days as indexed by the Longitudinal Interval Follow-up Evaluation (Keller et al., 1987) 12 months post-intervention
Secondary Depressive status at 12 month follow-up Presence of a Major Depressive Episode as indexed by the Longitudinal Interval Follow-up Evaluation (Keller et al., 1987) 12 months post-intervention
Secondary Depression symptoms at 12 month follow-up Score on the Beck Depression Inventory 12 months post-intervention
Secondary Autobiographical memory retrieval Scores for specific and alternating blocks of the alternating instructions autobiographical memory task (Dritschel et al., 2013) Measured within one week of completing the intervention
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4